Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[Q]: The release, while loaded with information about the research, fails to mention costs related to this new approach at any point. This is in spite of the fact that the paper provides what's necessaryto fulfill this criterion. The study authors wrote: "The easy access to the tumor site, the absence of the need for surgical removal of the tissue containing the T cells, the numbers of cells obtained with the harvest, and the ability to expand products in all patients with a relatively short process at a reasonable cost contrast sharply with several limitations of TIL ACT" (a current therapeutic approach to the disease). The release does a good job of spelling out the results of this phase1 trial by providing data showing that MILs can target and kill cancer cells. It shows that in more than half of the study's patients, their cancers had shrunk by at least half. In 15 of the 22 patients, their cancers did not progress for nearly a year after the MILs therapy. This wasn't a controlled study, so it's unclear how these patients would have fared without the MILs treatment, and the release could have attempted to provide some insight on that point. But we're pleased that the release focuses appropriately on the apparent safety of the approach, rather than trying to make claims about survival benefits that aren't supportable by this kind of small, uncontrolled study. The release also explains that the research provides information suggesting which patients might benefit best from this approach, and that other research at this cancer center is centered on testing this approach on different forms of cancer. We'll give this criterion a satisfactory rating since the release specifically spells out, "None of the participants had serious side effects from the MILs therapy." However, the study is really too small, and the timespan too short, to comment substantively on the possible harms that might be seen if and when the treatment is more widely used. The research paper actually makes the point that the new procedure doesn't require the "surgical removal of tissue," and the procedure can be done at bedside rather than an operating suite. Butthe removal of cells from the bone marrow is still an invasive procedure that carries its own risk of infection or other problems. The release would have benefited from at least mentioning this aspect. The release makes a very good effort to objectively describe a technically complicated trial. It defines the trial at least twice as being "small" and calls it a "pilot," suggesting that caution is appropriate when considering the results. It effectively explains the process involved in the treatments, including what was learned regarding the growth of cells in the lab after harvesting. It also points to the fact that while tumor-infiltrating lymphocytes (TILs) can only be retrieved from a quarter of the patient candidates for this technique, MILs were obtained from all of the patients in this study, suggesting that they may be a better tool for this therapy. Describing multiple myeloma as "the second most common cancer originating in the blood" doesn't add much to our understanding of this disease. However, other statistics provide context regarding the scope of the problem in the United States. We'll give it a pass. The funding sources for this research are listed in an end note in the release. No conflict of interest information is provided in the release, although the research paper discloses no conflicts. The release does mention that other forms of this adoptive T cell therapy use different cells, suggesting that other approaches are possible. The release also notes, "Three days before the injections of expanded MILs, patients received high doses of chemotherapy and a stem cell transplant, standard treatments for multiple myeloma." The release points out that "several U.S. cancer centers have conducted similar experimental treatments" but adds that Johns Hopkins is the only one using the MIL cells. It also points to several other ongoing clinical trials at Hopkins that build on the findings of this small study. Using the terms "pilot" and "experimental," the release signals that availability is very limited. We like the fact that the headline itself defines this as a "pilot" clinical trial and that the lede says that it is "what is believed to be the first small clinical trial of its kind." Those kinds of qualifiers both declare the specifics of the research and also provide informative caveats, allowing the reader to gauge how much credence to give to the findings. All too many other medical releases fail to provide this measured approach. This release is conservative throughout in its choice of language in describing this research which, based on its findings, might be ripe for exaggeration.
[A]: Pilot clinical trial finds injected immune cells safe in multiple myeloma patients

[Q]: The World Health Organisation has urged countries to widen testing to contain the virus. Malaysia's tally of infections has jumped six-fold in just ten days to more than 1,500, exceeded only by China, South Korea and Japan in Asia. By the end of the week, Malaysia will double daily testing capacity to 7,000, before stepping that up to 16,500 by the first week of April, the official, Noor Hisham Abdullah, said. "We are preparing for the worst scenario, but hope for the best outcomes," Noor Hisham, the director general of Malaysia's health ministry, added in a text message late on Monday. "Once we have the capacity ready, we will scale up active case detection, testing, isolation and treatment." Ministry data shows Malaysia had done 17,923 tests by Monday, when the biggest daily increase of 212 new infections took the country's total to 1,518. That works out to about 560 tests per million people, fewer than neighboring Singapore's 4,500 tests per million, according to the city-state's most recent data, but well above Indonesia's single-digit figures. Malaysia has recorded at least 14 virus deaths. It has linked nearly two-thirds of its infections to a religious gathering last month near the capital, Kuala Lumpur, that the government says drew more than 16,000 people. The event is also linked to more than 100 cases across Southeast Asia. On Monday, Prime Minister Muhyiddin Yassin said Malaysia may extend beyond the end of the month travel and movement curbs imposed to contain the spread of the virus. [nL4N2BG1XK]
[A]: Malaysia steps up coronavirus tests as it braces for 'worst scenario'.

[Q]: A person carrying the novel coronavirus in Norway contaminates now on average 0.7 other individuals, Bent Hoeie told a news conference. The government's goal had been to limit the spread to maximum one other person. "Before we implemented tough restrictions, every contaminated person in Norway infected 2.5 other individuals on average," Hoeie said. "If this development had been allowed to continue, we would probably have been in the same situation that we have seen in some countries in Europe." The Norwegian government announced three weeks ago emergency shutdowns of many public and private institutions, including schools and kindergartens, sending the economy into a tailspin and triggering hundreds of thousands of layoffs. The government will decide on Wednesday whether to extend the restrictions beyond mid-April. It was not immediately clear which measures could be lifted, nor when they would be. Local authorities in the capital Oslo and Trondheim, Norway's third-largest city, have already said they will not reopen schools and nurseries by mid-April because they needed more time to prepare. The Norwegian Institute of Public Health (FHI) said on Monday the number of coronavirus cases in the country stood at 5,755 people, with 59 deaths. The FHI also estimated for the first time on Monday that around 14,000 people in total may be carrying the virus in Norway, or 0.26% of the population. "It is good news. It shows the restrictions have worked," Camilla Stoltenberg, the head of the institute, told public broadcaster NRK. "(But) we don't know which specific measures worked."
[A]:
Coronavirus epidemic 'under control' in Norway: health minister.